Sai Life Science Files for IPO with SEBI

Sai Life Science Ltd., a Hyderabad-based global pharmaceutical company backed by TPG Group, has filed preliminary papers with the Securities and Exchange Board of India (SEBI) for an initial public offering (IPO). This significant step will help the company raise funds to support its growth and operational needs.

IPO Details and Shareholder Information

Sai Life IPO will consist of a fresh issue of equity shares worth Rs 800 crore and an offer-for-sale of 6.15 crore shares, as stated in the draft red herring prospectus. Sai Quest Syn Pvt. will be the sole promoter-selling shareholder, while TPG Asia VII SF Pte Ltd., an affiliate of the TPG Group, plans to offload 4.57 crore shares. HBM Private Equity India will also participate by selling up to 68.62 lakh shares. Currently, Sai Quest Syn holds a 5.61% stake in the company, TPG owns 39.69% of the shares, and HBM Private Equity India has a 5.5% stake.

Utilisation of IPO Proceeds

According to the draft papers filed on Friday, Rs 600 crore of the IPO proceeds will be allocated for debt repayment, with the remaining funds used for general corporate purposes. The book-running lead managers for the issue are Kotak Mahindra Capital Company Ltd., IIFL Securities Ltd., Jefferies India Pvt., and Morgan Stanley India Co.

Company Profile and Services

Sai Life Sciences offers comprehensive services across the drug discovery, development, and manufacturing chain. The company supports the development of small-molecule new chemical entities for global pharmaceutical innovators and biotechnology firms. As of March 31, 2024, Sai Life Sciences’ Contract Development and Manufacturing Organization (CDMO) product portfolio included over 150 innovator pharmaceutical products, with 38 products supplied for the manufacturing of 28 commercial drugs.

Excited about new investment opportunities? Discover our Upcoming IPO and be the first to invest in the next big thing. Secure your financial future today!

Conclusion: The IPO marks a pivotal moment for Sai Life Science Ltd., enabling the company to leverage capital markets for growth and debt management. With strong backing from prominent investors and a robust product portfolio, Sai Life Sciences is well-positioned to continue its contributions to the pharmaceutical industry.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.